
    
      This is a long-term continuation study to provide continuing treatment to subjects who
      completed study HGS1006-C1056 in the United States. This study is to evaluate the long-term
      safety and efficacy of belimumab (LymphoStat-Bâ„¢) in subjects with SLE disease.
    
  